Homologous recombination proficiency in ovarian and breast cancer patients
2021 · BMC Cancer · 83 citations
https://doi.org/10.1186/s12885-021-08863-9
L
Laura Stanbery
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
85
Papers
1.7K
Citations
20
h-index
32
i10-index
Laura Stanbery is an academic researcher from Gradalis (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer Genomics and Diagnostics & Ovarian cancer diagnosis and treatment. The author has an h-index of 20, co-authored 73 publications.
ORCID: 0000-0001-7251-4076Papers by this author
worksFDA efficiency for approval process of COVID-19 therapeutics
2020 · Infectious Agents and Cancer · 17 citations
https://doi.org/10.1186/s13027-020-00338-z
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
2022 · Communications Medicine · 13 citations
https://doi.org/10.1038/s43856-022-00163-y
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
2025 · Scientific Reports · 4 citations
https://doi.org/10.1038/s41598-025-90136-7
Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]
2021 · Gynecologic Oncology Reports · 3 citations
https://doi.org/10.1016/j.gore.2021.100740
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer
2024 · Gynecologic Oncology · 1 citations
https://doi.org/10.1016/j.ygyno.2024.11.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat